Overview Cough Reduction in IPF With Nalbuphine ER Status: COMPLETED Trial end date: 2025-04-24 Target enrollment: Participant gender: Summary The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.Phase: PHASE2 Details Lead Sponsor: Trevi TherapeuticsTreatments: Nalbuphine